Respiratory tract toxicity represents a significant cause of attrition of inhaled drug candidates targeting respiratory diseases. One of the key issues to allow early detection of respiratory toxicities is the lack of reliable and predictive in vitro systems. Here, the relevance and value of a physiologically relevant 3D human airway in vitro model (MucilAir) were explored by repeated administration of a set of compounds with (n ¼ 8) or without (n ¼ 7) respiratory toxicity following inhalation in vivo. Predictability for respiratory toxicity was evaluated by readout of cytotoxicity, barrier integrity, viability, morphology, ciliary beating frequency, mucociliary clearance and cytokine release. Interestingly, the data show that in vivo toxicity can be predicted in vitro by studying cell barrier integrity by transepithelial electrical resistance (TEER), and cell viability determined by the Resazurin method. Both read-outs had 88% sensitivity and 100% specificity, respectively, while the former was more accurate with receiver operating characteristic (ROC) AUC of 0.98 (p ¼ .0018) compared with ROC AUC of 0.90 (p ¼ .0092). The loss of cell barrier integrity could mainly, but not fully, be attributed to a loss of cell coverage in 6 out of 7 compounds with reduced TEER. Notably, these effects occurred only at 400 mM, at concentration levels significantly above primary target cell potency, suggesting that greater attention to high local lung concentrations should be taken into account in safety assessment of inhaled drugs. Thus, prediction of respiratory toxicity in 3D human airway in vitro models may result in improved animal welfare and reduced attrition in inhaled drug discovery projects.
Inhalation is the key route for delivery of therapeutic agents to treat respiratory diseases such as asthma and chronic obstructive pulmonary disease. Inhaled corticosteroids, b2-agonists and antimuscarinics represent standard care in respiratory diseases (Chauhan and Ducharme, 2014 ) and a number of additional therapeutic opportunities are being explored (Wain et al., 2017) . The utility of the inhaled route for drug delivery in respiratory diseases presents a great advantage with topical access to the diseased tissue and a low systemic exposure with associated reduction in the potential for systemic side effects. However, unacceptable toxicity in the respiratory tract represents a major obstacle in the development of inhaled therapies, and has been reported to account for approximately 30% of inhaled project closures (Cook et al., 2014) . Respiratory toxicities have typically been identified at a relatively late stage in preclinical testing as part of the comprehensive assessment undertaken during in vivo toxicity studies with the aim to identify therapeutic margins, maximal tolerable concentrations and reversibility of any noted adverse effects (Ahuja et al., 2017; Hayes and Bakand, 2014) . To this point, improved early assessment and prediction of the toxicity potential of new molecules would add significant value in terms of the potential to reduce late stage compound attrition, increase quality of drug candidates, and improve animal welfare by replacement, reduction or refinement of animal usage in preclinical toxicity testing of novel inhaled drugs. One of the key limitations for early detection of respiratory toxicities so far has been around development of reliable and predictive in vitro models.
The airway epithelium represents a barrier with a role in protection of the airways and is one of several key target sites for toxicity in the respiratory tract. Therefore, a major focus has been on developing in vitro models representing this region of the lung. Primary airway epithelial cells cultured at air-liquid interphase represent physiologically relevant models of the human airway consisting of ciliated cells, mucus secreting goblet cells and basal cells (Balharry et al., 2008; Huang et al., 2013) , and are now commercialized under trade names such as MucilAir and EpiAirway by Epithelix S arl (Geneva, Switzerland) and MatTek Corporation (Ashland, MA, US), respectively. So far, toxicity evaluations in such 3D human airway in vitro models have focused on lung irritancy of environmental toxic agents such as smoke, ozone, formaldehyde, CdCl 2 , and nanoparticles (Balharry et al., 2008; Cao et al., 2017; Huang et al., 2013; Kuper et al., 2015; Rothen-Rutishauser et al., 2008) . Here, we, to the best of our knowledge, for the first time explore the relevance, value and potential application of the MucilAirmodel to predict in vivo respiratory toxicity in the context of inhaled drug candidates for treatment of respiratory diseases.
We focused our in vitro investigation in the MucilAir model around a set of 14 inhaled drugs or drug candidates and CdCl 2, a known toxic agent, as a positive control. These were divided into compounds with (n ¼ 8) or without (n ¼ 7) respiratory toxicity based on historical data from limited dose-range and dose duration in vivo studies (Table 1 ). The compounds with toxicities had previously shown to induce a range of different adverse responses in the respiratory tract, mostly observed as histopathological changes in the lung in animal toxicology studies (Table 1 ). In addition, pentamidine, an approved inhaled drug associated with respiratory adverse events, (TAPS group, 1990 , Katzman et al., 1992 and salmeterol in the free base form (Owen et al., 2010) were included as positive controls. A range of different parameters such as cytotoxicity, cell barrier integrity, viability, morphology, ciliary beating frequency (CBF), mucociliary clearance (MCC), and cytokine release were analyzed for predictive accuracy for respiratory toxicity. With this approach, we demonstrate that a 3D human airway in vitro model is capable of predicting the potential for drug-induced adverse effects in the respiratory tract, by monitoring the loss of barrier integrity and cell viability as measured by transepithelial electrical resistance (TEER) and Resazurin, respectively. In conclusion, the 3D human airway in vitro model has a clear potential to reduce compound attrition due to respiratory toxicity, and insight from this work could help to guide the development of future inhaled therapies for respiratory diseases.
MATERIALS AND METHODS
3D human airway in vitro model. Airway cells were obtained from patients undergoing surgical polypectomy. All experimental procedures were explained in full, and all subjects provided informed consent. The study was conducted according to the declaration of Helsinki on biomedical research (Hong Kong amendment, 1989) , and received approval from the local ethics commission. MucilAir (Epithelix S arl, Geneva, Switzerland) airway epithelia, reconstituted with a mixture of human nasal cells isolated from a panel of 14 different donors, were cultured at the air liquid interface in MucilAir culture medium (Epithelix S arl, Geneva, Switzerland), in 24-well plates with 6.5-mm Transwell inserts (Corning). The cell culture medium was changed at each sampling point or every 2-3 days for those wells not being sampled. The nasal version of MucilAir were used as surrogate for bronchial epithelia due to availability, quality and close resemblance in gene expression levels, morphology and function (Iskandar et al., 2013; McDougall et al., 2008; Thavagnanam et al., 2014) .
Testing strategy. All compounds were synthesized at AstraZeneca, except CdCl 2 , which was purchased from Sigma. The compounds were dissolved in DMSO and diluted in a buffered saline solution (0.9% NaCl, 1.25 mM CaCl 2 , 10 mM HEPES) to reduce the final concentration of DMSO to 0.8% (v/v). Test compounds (10 ll) were applied daily at 4, 40, and 400 mM on the apical surface of MucilAir cultures and left to incubate for 6 h prior to replacing with fresh medium. This was repeated for a period of 12 days. Each treatment was run as 4 replicates on each occasion. Culture supernatants were collected and stored at À80 C for future analysis. The Transwell membranes containing the 3D airway cells were fixed for 30 min in 4% Formaldehyde-PBS (with Ca/Mg) at RT, washed in PBS and stored at 4 C until processing for immunohistochemistry.
Measurements. TEER and CBF were assessed as previously described (Huang et al., 2017) . Cell viability was measured by Resazurin test at termination and cytokines assessed at indicated time-points as previously described (Huang et al., 2013) . Cytotoxicity was measured by quantification of lactate dehydrogenase (LDH) in supernatants by Cytotoxicity Detection KitPLUS (Roche) according to manufacturer's instructions. MCC was assessed as previously described (Huang et al., 2017) . In short, 30 mm polystyrene microbeads (Sigma,) were added on the apical side of the MucilAir cells. The movement of the microbeads was recorded with a Sony XCD-U100CR camera at 2 frames per second, on an Axiovert 200 M microscope (Zeiss), at room temperature. A total of 50 images were recorded and more than 1000 beads were tracked and the velocity of MCC (mm/s) was calculated using Image-Pro Plus software (version 6.2, Media Cybernetics). Three movies were taken and analyzed per insert.
Immunohistochemistry and determination of cell coverage grade. Membranes were permeabilised with 0.5% Triton-X100 in PBS buffer for 20 min, blocked with 2.5% BSA, 5% goat serum, 0.05% Tween-20 in PBS for 30 min. Cells was incubated with antiTubulin (NBP2-00812, NovusBio), and antiMuc5AC (MS145P1, Thermo Scientific) in the block buffer for 60 min, followed by Alexa 488 coupled mouse IgG2A (A21131, Invitrogen) and Alexa 568-Mouse IgG1 (A21124, Invitrogen) for 45 min in the dark. All steps were performed at room temperature. The membranes were mounted on glass slides in Vectashield antifade mounting medium containing DAPI stain (Vector Lab) and evaluated under fluorescent microscope Ax70 (Olympus). Images were captured by confocal microscope LSM880 (Zeiss) connected to ZEN 2.3 software (Zeiss) and illustrated by using Photoshop, version 11 (Adobe). The cell coverage grade was determined on blinded samples by visual estimate of the confluency area: 70%-100% (grade 4); 30%-70% (grade 3); 10%-30% (Grade 2); <10% (grade 1); loss of all cells (grade 0).
Statistics. The method detection limit (MDL) is defined as the minimum value of a substance that can be distinguishable from method blank with 99% confidence and were determined according the U.S. Environmental Protection Agency method (US EPA 2016). Quality of the assays was determined by the Zeta-factor (Z') method (Zhang et al. 1999) . All other statistical calculations were performed by GraphPad prism 7.0 software (GraphPad Software, San Diego, California). Cut-off values were determined by Youden's index (J), i.e. {J ¼ sensitivity þ specificity -1} (Youden, 1950) .
RESULTS

Measurement of Cell Barrier Integrity in 3D Human Airway Epithelial Cell Cultures
The fully differentiated MucilAir 3D human airway cultures showed a nonsignificant difference in cell barrier integrity as measured by TEER between assay occasions as determined with 1-way ANOVA with a mean TEER value across studies of 440 (SD 70) X cm 2 (n ¼ 3). However, we noted an intra-assay time-point dependent shift in TEER values with an average intra-assay coefficient of variance (intra-assay CV) of 16.9%. Therefore, in order to compare compound effects between different assay occasions and assay time-points, the change in TEER value from vehicle was normalized against vehicle control on each day. By this approach, the MDL of the TEER read-out was 25.5% (n ¼ 40) with an intra-assay CV of 9.4% (95% CI 6.7-12.1) and an average Z-prime of 0.75 per plate. In order to predict respiratory toxicity, a test-set of 15 compounds were evaluated in the MucilAir 3D human airway epithelial model, by repeat application of compounds to the apical side, for 6 h per day for 12 days, to represent a prolonged residence time and to mimic the inhaled route. The compounds were divided into 2 different categories based on historical data, compounds with (n ¼ 8) and without (n ¼ 7) demonstrated respiratory toxicity following inhalation (Table 1) . Cell barrier integrity was measured for all compounds at 4, 40, and 400 mM and a reduction of TEER over MDL was evident in 7 out of 8 compounds with known toxicity at the highest tested dose of 400 mM after 12 repetitive doses ( Figure 1A ). Importantly, a reproducible and time-dependent loss of barrier integrity was found for all compounds with known respiratory toxicity in animals (n ¼ 7), while all compounds without respiratory toxicity and pentamidine, a drug with lung irritancy side-effects in human, were below MDL (Figs. 1B and 1C and Supplementary Figure 1A) . Next, the most accurate time-point to predict respiratory toxicity was determined by area under the receiver operating characteristic (ROC) curve analysis. A reduction in TEER from baseline significantly predicted toxicity after 1-3 and 8-12 consecutive days of drug treatment, respectively and most accurately at day 12 with ROC AUC of 0.98 (95% CI, 0.93-1.04, p ¼ .0018) (Supplementary Figs. 2B and 4A) . To be able to distinguish between toxic and nontoxic compounds, a cut-off value was calculated to provide optimum sensitivity at the highest possible specificity by Youden analysis. The sensitivity and specificity at a cut-off value of 32% decrease in the TEER signal were 88% and 100%, respectively at day 12.
Measurement of Cell Viability
Cell viability was detected by reduction of resazurin by measuring fluorescence after addition of the detection probe to the cell cultures at the termination of the experiment. The vehicle treated samples had a mean RFU of 12800 with inter-assay CV of 15% (n ¼ 3) and a mean intra-assay CV of 14% (95% CI, 10.2-17.8) resulting in a MDL of 39% (n ¼ 26). In drug treated samples, 5 out of 8 toxic drugs showed a reduction of cell viability beyond MDL, including salmeterol in the free base form with a 48% reduction compared with vehicle ( Figure 2A ). Cell viability measured at termination of the experiment showed a significant alignment towards TEER ( Figure 2B ) and predictive accuracy for respiratory toxicity with ROC AUC of 0.90 (95% CI, 0.71-1.09, p ¼ .0092) ( Figure 4A ). Cell viability had similar sensitivity for predicting toxicity as TEER, with 88% sensitivity and 100% specificity, respectively at cut-off values of 14% reduction in viability compared with vehicle. These data imply that respiratory in vivo toxicity of inhaled drugs could be captured in vitro by assessing both TEER and cell viability.
Correlation of Cell Coverage Against Barrier Integrity and Cell Viability First, the morphology of vehicle treated MucilAir cultures was assessed on whole mount preparations by immunohistochemistry against Tubulin B to detect ciliated cells and cytoskeleton, MUC5AC to detect mucin in goblet cells and DAPI as nuclear stain. The airway epithelium cultures were fully confluent and well differentiated as the majority of cells on the apical side were ciliated epithelial cells, and a minority of goblet cells (Supplementary Figure 2A) . In the cross section, the cells were arranged in a pseudostratified pattern with some variations of the thickness of the epithelium. Thus, the 3D human airway epithelial cultures showed a physiological resemblance to a human ciliated epithelial layer in the airway.
Next, a cell coverage grading system based on visual estimates of cell confluence area was developed to potentially link loss of TEER and cell viability to cell confluency. First, the epithelial damage was examined for AZ4 at 400 mM on treatment exposure, correlating with a decrease in TEER signal ( Figure 3B ). This was visible by a progressive loss of cells, starting at the peripheral area at early time points and a total cell loss at later time points ( Figure 3A) . Second, the epithelial morphology, TEER signal and cell viability measured by the Resazurin method were compared between all 15 compounds at all tested concentrations at the end of the experiment. Loss of cell coverage was evident in 6 out of 7 compounds with reduced TEER and correlated to both TEER and cell viability ( Figure 3C and Supplementary Figure 2B ). The only exception was salmeterol in the free base form, which showed a reduction in TEER and cell viability, while cell coverage remained in the range observed for vehicle treatment. Growth Factor beta), MCC and CBF were assessed on days 2, 4, 8, and 12 in the 3 D human airway in vitro system. A 2-to 3-fold increased release of LDH above the MDL (63 nM) was observed for 4 out of the 8 toxic compounds (Supplementary Figure 3A) . The cytotoxicity for these few compounds tended to correlate with loss in tissue integrity, while no increase in LDH was found for compounds without known in vivo toxicity. Regarding cytokine release, only CdCl 2 released robust amounts of cytokines as exemplified by IL-8 (30-70 ng/ ml), and AZ4 induced IL-8 at low but significant levels at day 8 (3 ng/ml) (Supplementary Figure 3B) . However, CBF was reduced in the samples with complete loss of cell coverage (Supplementary Figure 4) . Similarly, MCC was assessed in the initial phase of the evaluation with variable results. MCC needs further indepth studies to determine its application in this model. Overall, the separation was insignificant between toxic and nontoxic compounds for LDH, IL-8, and CBF. Thus, these read-outs proved nonpredictive for respiratory toxicity ( Figure 4B ).
Measurement of
DISCUSSION
Toxicity in the respiratory tract represents a major obstacle in the development of inhaled therapeutics, and is often not identified until late stage in vivo toxicity studies resulting in project closure. One of the key issues has been the development of reliable and predictive in vitro systems to permit earlier detection of respiratory toxicities and potential liabilities. This investigation explored the capability of a 3D human airway in vitro system, MucilAir (Huang et al., 2013) , to predict respiratory toxicity in vivo, by repeated administration of compounds intended for chronic treatment of respiratory disease by inhalation. To the best of our knowledge, this is the first study with a direct application of inhaled drug candidates in a physiologically relevant 3D human airway in vitro model for evaluation of associated respiratory toxicity in vivo.
The data demonstrate that both cell barrier integrity and cell viability as measured by TEER and Resazurin, respectively, can be utilized as predicting factors for respiratory toxicity of inhaled drugs in the MucilAir model ( Figure 4A ). The TEER signal was significantly reduced for all but one (pentamidine) of the studied compounds with confirmed pulmonary toxicity, while not affected by any of the compounds without respiratory liabilities. The accuracy as determined by area under the ROC curve was above 0.9 after 12 repeated doses with 86% sensitivity at 100% specificity for both TEER and cell viability, which can be considered as excellent predictability of respiratory toxicities (Hajian-Tilaki, 2013 , Pencina et al., 2008 . The TEER read-out has some clear advantages compared with cell viability. First, due to a higher degree of significance shown here, but more importantly by allowing measurements of toxicity over time. The loss in barrier integrity and cell viability also correlated with cell confluency for 6 out of 7 compounds with a reduction in TEER, suggesting that the major reason for toxicity for these compounds is related to loss in viability. All other measured read-outs were nonsignificant for predicting lung toxicity. For example, the released amounts of LDH and cytokines were barely over MDLs for the majority of treatments. This is in line with observations that 3D human airway cells are relatively resistant to LDH and cytokine release following insults (Zavala et al., 2016) .
These correlations to respiratory toxicity in vivo only occurred at relatively high compound concentrations, namely 400 mM (Figure 1 ). Following inhalation, the lung, and the epithelium in particular, is exposed to highly heterogeneous drug concentrations, resulting in high regional concentrations. Additionally, the human lung lining fluid volume is estimated to 30 ml (Rennard et al., 1986) , and even modest inhaled doses are likely to result in high instant concentrations when distributed in this small volume. Our recent inhouse experiments suggest that whole lung concentrations reach approximately 70-2000 mM (4 different compounds) in rat inhalation studies at toxicologically relevant dose ranges (Å berg et al., unpublished data) . Furthermore, applications of robust margins to any confirmed toxicity in animal studies is expected in the context of respiratory toxicity risk assessment (Alton et al., 2012; Tepper et al., 2014) . In addition, as with many other toxicities, nonadaptive adverse tissue responses in lung tend to accumulate over time. Taken together, it is plausible that measurement of cell barrier integrity and cell viability in vitro by repeated administration at high concentrations are relevant for in vivo respiratory toxicity, as a consequence of high local levels in lung and by mimicking accumulation of adverse responses in the respiratory tract over time. Neither barrier integrity nor cell viability were significantly affected compared with vehicle controls by pentamidine, which was included in our evaluations as an agent associated with respiratory toxicity. Pentamidine, is approved for oral inhalation for the prevention of Pneumocystis jiroveci pneumonia in highrisk, HIV-infected patients (NDA 019887, 2010) , but has been associated with wheezing and cough in humans (Katzman et al., 1992; TAPS group, 1990 ). Thus, the tolerability profile appears to be incompatible with chronic therapy. However, to our knowledge, there is limited information on toxicity following inhaled exposure in animals. The data set presented here was based on a limited set of compounds with either confirmed or estimated therapeutic doses at levels generally not >2 mg. In this context pentamidine is an outlier with a therapeutic dose range >100 mg. As our experimental set-up was based on using the same concentration range, despite differences in potency and therapeutic levels, the relevant concentrations may not have been achieved in the case of pentamidine. Another plausible explanation for intact barrier, could be that cough and wheezing by pentamidine in humans are related to stimulation of sensory nerve receptors (Nasra and Belvisi, 2009) or induction of structural and inflammatory airway mucosal changes (Chung and Pavord, 2008 ) that may not be detected in this in vitro airway model.
Salmeterol is approved for inhalation treatment in respiratory indications as a xinfoate salt, and this form is not associated with lung toxicity (Owen et al., 2010) . In this study, we included the free base form of salmeterol as predictive parameter for toxicity on the basis of published data suggesting that this form was associated with unacceptable respiratory tract irritancy/toxicity (Owen et al., 2010) . Interestingly, we found that salmeterol in the free base form reduced TEER and cell viability, but not cell coverage (Figs. 1 and 2 and Supplementary Figure  3B) . TEER measurement is a widely accepted quantitative technique to measure the integrity of tight junction dynamics in cell models, and TEER values are strong indicators of the integrity of the cellular barriers (Srinivasan et al., 2015) . Thus, it is possible that salmeterol free base affects the tight junctions at high concentrations resulting in loss of TEER. This may imply that barrier integrity measured by TEER may be indicative of toxicity also in the absence of effects on cell coverage. However, it is also important to consider that the sole reduction in TEER represents a more limited response where translation to toxicity is not absolute, and that the salt form of salmeterol is widely used without association to respiratory toxicity. In addition, in contrast to pentamidine, the therapeutic dose of salmeterol is relatively low. This reflects that the extent of the response, the dosage form as well as the therapeutic dose are important factors to take into consideration in the context of decision making about compound progression.
This study could potentially be biased due to a low study power (n ¼ 15) and inclusion of a limited set of chemical drug classes, with a focus on kinase-inhibitors and phosphodiesterase-inhibitors in the group of toxic compounds. In addition, most of the toxicities reported here were observed in rats and dogs, while the in vitro model is based on human cells. As mechanisms for toxicity were not determined, there is a potential for species differences. However, based on the outcome of these experiments, it appears that these differences were not significant, as reflected in the robust predictability. Furthermore, the in vivo responses comprised of a range of phenotypes such as bronchopneumonia, alveolitis, edema and/or changes in cell morphology, while the in vitro model evidently only addresses the direct impact on the epithelium. There are evident opportunities to further enhance the power of the predictability assessment by incorporation of novel inhaled drug candidates as they become available, as well as drugs with lung irritancy and further assess viability in this model during the treatment phase. Also development of more complex coculture systems and dry powder aerosol delivery systems could potentially enhance the resolution by replicating the multicellular environment of the respiratory tract and the in vivo exposure conditions. In addition, further evaluation of viability measures in cell line systems, such as THP-1 cells, are warranted due to the close alignment between cell viability and respiratory toxicity in the 3D human airway in vitro systems in this study.
In a drug discovery context, these results suggest that measurements of cell barrier integrity and cell viability in a 3D human airway in vitro model represent a valuable addition to the tools which can be utilized to reduce the risk of attrition of inhaled drug candidates in comprehensive regulatory in vivo toxicity studies. Furthermore, our data emphasize that a larger attention to deleterious effects in vitro at concentrations well above an acceptable therapeutic index should be taken into account in predicting risk for respiratory toxicity. In summary, this approach may potentially reduce the risk for late-stage drug attrition, reduce the number of animals used in early preclinical toxicity assessments and thus improve the safety profile of novel drugs for human respiratory diseases.
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